Skip to main content
SpringerLink
Log in

Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion

  • Published:
Pituitary Aims and scope Submit manuscript

Abstract

Background Few data are presently available on the effective control of cavernous sinus (CS) invasion of invasive prolactinomas. The aim of this retrospective study, through a mean period of 5 years follow up, is to observe the tumor shrinkage of CS invasive prolactinomas, as well as PRL normalization with bromocriptine therapy. Methods 68 patients met the criteria of invasive prolactinomas (Grade III or IV in the classification scheme of Knosp and colleagues; serum PRL level greater than 200 ng/ml). 33 patients underwent bromocriptine therapy as the initial treatment, and 14 of these 33 had combined treatment with microsurgery and/or radiotherapy. The other 35 patients received microsurgery as the primary treatment, after which two patients had normal PRL without taking bromocriptine and other 33 patients received bromocriptine treatment after microsurgery. Results Tumor volume on magnetic resonance images had completely disappeared in 50 patients (74%), while all the other 18 patients had residual tumor in the parasellar areas, invading the CS, and 14 patients had a secondary empty sella due to tumor shrinkage. Of those 14 patients, seven still had elevated PRL levels; five had optic chiasmal herniation by different degrees (P < 0.05). There were 49 patients with normal PRL levels (72%); five patients with PRL levels more than 200 ng/ml. After the treatment, 14 patients with tumor volume disappearance on MR images and PRL normalization therefore withdrew from bromocriptine therapy. During a subsequent one-and-a-half-year follow-up, tumor recurrence and PRL increase were not found in those 14 patients. Twenty-seven patients maintained normal PRL levels with low-dose bromocriptine, of which 20 patients had their tumor disappear while seven patients had CS residual tumor. Conclusions About three-fourths of prolactinomas with CS invasion can be effectively controlled not only with regard to tumor volume disappearance but also in serum PRL normalization. Residual tumor in the CS areas with PRL normalization and no pressure symptoms can be treated with low-dose of bromocriptine so as to achieve long-term tumor volume control and endocrine control. Great attention should be paid to CS residual tumors accompanying the empty sella, especially in cases with optic chiasmal herniation.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Abbreviations

CS:

Cavernous Sinus

CSF:

Cerebrospinal Fluid

DA:

Dopamine Agonist

ICA:

Internal Carotid Artery

PRL:

Prolactin

References

  1. Cottier JP, Destrieux C, Brunereau L et al (2000) Cavernous sinus invasion by pituitary adenoma: MR imaging. Radiology 215:463–469

    PubMed  CAS  Google Scholar 

  2. Knosp E, Steiner E, Kitz K et al (1993) Pituitary adenomas with invasion of the cavernous sinus space: a magnetic resonance imaging classification compared with surgical findings. Neurosurgery 33:610–618

    Article  PubMed  CAS  Google Scholar 

  3. Wu ZB, Yu CJ, Su ZP et al (2006) Bromocriptine treatment of invasive giant prolactinomas involving the cavernous sinus: results of a long-term follow up. J Neurosurg 104(1):54–61

    Article  PubMed  CAS  Google Scholar 

  4. Delgrange E, Sassolas G, Perrin G, et al (2005) Clinical and histological correlations in prolactinomas, with special reference to bromocriptine resistance. Acta Neurochirurgica (Wien) 147:751–758

    Article  CAS  Google Scholar 

  5. Delgrange E, Duprez T, Maiter D (2006) Influence of parasellar extension of macroprolactinomas defined by magnetic resonance imaging on their responsiveness to dopamine agonist therapy. Clin Endocrinol 64:456–462

    Article  Google Scholar 

  6. Laws ER Jr, Thorner MO, Vance ML (1996) Bromocriptine therapy for prolactin-secreting pituitary adenomas. Neurosurg Focus 1(1):E4

    Article  PubMed  Google Scholar 

  7. Colao A, Di-Sarno A, Landi ML et al (1997) Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage. J Clin Endocrinol Metab 82(11):3574–3579

    Article  PubMed  CAS  Google Scholar 

  8. Essais O, Bouguerra R, Hamzaoui J et al (2002) Efficacy and safety of bromocriptine in the treatment of macroprolactinomas. Ann Endocrinol (Paris) 63(6 Pt 1):524–531

    CAS  Google Scholar 

  9. Shrivatava RK, Arginteanu MS, King WA et al (2002) Giant prolactinomas: clinical management and long-term follow up. J Neurosurg 97:299–306

    Google Scholar 

  10. Yu C, Wu Z, Gong J (2005) Combined treatment of invasive giant prolactinomas. Pituitary 8(1):61–65

    Article  PubMed  CAS  Google Scholar 

  11. Couldwell WT, Weiss MH, Rabb C et al (2004). Variations on the standard transsphenoidal approach to the sellar region, with emphasis on the extended approaches and parasellar approaches: surgical experience in 105 cases. Neurosurgery 55:539–550

    Article  PubMed  Google Scholar 

  12. Losa M, Mortini P, Barzaghi R et al (2002) Surgical treatment of prolactin-secreting pituitary adenomas: early results and long-term outcome. J Clin Endocrinol Metab 87:3180–3186

    Article  PubMed  CAS  Google Scholar 

  13. Sieck JO, Niles NL, Jinkins JR et al (1986) Extrasellar prolactinomas: successful management of 24 patients using bromocriptine. Horm Res 23(3):167–176

    PubMed  CAS  Google Scholar 

  14. van’t Verlaat JW, Croughs RJ, Hendriks MJ et al (1990) Results of primary treatment with bromocriptine of prolactinomas with extrasellar extension. Can J Neurol Sci 17(1):71–73

    Google Scholar 

  15. Delgrange E, Maiter D, Donckier J (1996) Effects of the dopamine agonist cabergoline in patients with prolactinoma intolerant or resistant to bromocriptine. Eur J Endocrinol 134:454–456

    PubMed  CAS  Google Scholar 

  16. Verhelst J, Abs R, Maiter D et al (1999) Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab 84(7):2518–2522

    Article  PubMed  CAS  Google Scholar 

  17. Fraioli B, Esposito V, Santoro A et al (1995) Transmaxillosphenoidal approach to tumors invading the medial compartment of the cavernous sinus. J Neurosurg 82:63–69

    Article  PubMed  CAS  Google Scholar 

  18. Frank G, Pasquini E (2006) Endoscopic endonasal cavernous sinus surgery, with special reference to pituitary adenomas. Front Horm Res 34:64–82

    PubMed  Google Scholar 

  19. Hashimoto N, Kikuchi H (1990) Transsphenoidal approach to infrasellar tumors involving the cavernous sinus. J Neurosurg 73:513–517

    PubMed  CAS  Google Scholar 

  20. Jho HD, Carrau RL (1997) Endoscopic endonasal transsphenoidal surgery: experience with 50 patients. J Neurosurg 87(1):44–51

    PubMed  CAS  Google Scholar 

  21. Kitano M, Taneda M (2001) Extended transsphenoidal approach with submucosal posterior ethmoidectomy for parasellar tumors. Technical note. J Neurosurg 94:999–1004

    CAS  Google Scholar 

  22. Sabit I, Schaefer SD, Couldwell WT (2000) Extradural extranasal combined transmaxillary transsphenoidal approach to the cavernous sinus: a minimally invasive microsurgical model. Laryngoscope 110:286–291

    Article  PubMed  CAS  Google Scholar 

  23. Landolt AM, Lomax N (2000) Gamma knife radiosurgery for prolactinomas. J Neurosurg 93(Suppl 3):14–18

    PubMed  Google Scholar 

  24. Pan L, Zhang N, Wang EM et al (2000) Gamma Knife radiosurgery as a primary surgical treatment for prolactinomas. J Neurosurg 93(suppl 3):10–13

    PubMed  Google Scholar 

  25. Pouratian N, Sheehan J, Jagannathan J et al Gamma knife radiosurgery for medically and surgically refractory prolactinomas. Neurosurgery 59:255–266

  26. Petrovich Z, Yu C, Giannotta SL et al Gamma knife radiosurgery for pituitary adenoma: Early results. Neurosurgery 53:51–59

  27. Pollock BE, Nippoldt TB, Stafford SL et al (2002) Results of stereotactic radiosurgery in patients with hormone-producing pituitary adenomas: factors associated with endocrine normalization. J Neurosurg 97:525–530

    PubMed  Google Scholar 

  28. Shin M, Kurita H, Sasaki T et al (2000) Stereotactic radiosurgery for pituitary adenoma invading the cavernous sinus. J Neurosurg 93(suppl 3):2–5

    PubMed  Google Scholar 

  29. Laws ER Jr, Vance ML (1999) Radiosurgery for pituitary tumors and craniopharyngiomas. Neurosurg Clin North Am 10:327–336

    Google Scholar 

  30. Morange-Ramos I, Regis J, Dufour H et al (1998) Gamma-knife surgery for secreting pituitary adenomas. Acta Neurochir (Wien) 140(5):437–443

    Article  CAS  Google Scholar 

  31. Johnston DG, Hall K, Kendall-Taylor P et al (1984) Effect of dopamine agonist withdrawal after long-term therapy in prolactinomas: studies with highdefinition computerised tomography. Lancet 2:187–192

    Article  PubMed  CAS  Google Scholar 

  32. Wang C, Lam KSL, Ma JT et al (1987) Long-term treatment of hyperprolactinaemia with bromocriptine: effect of drug withdrawal. Clin Endocrinol (Oxf) 27:363–371

    CAS  Google Scholar 

  33. Zarate A, Canales ES, Cano C et al Follow-up of patients with prolactinomas after discontinuation of long-term therapy with bromocriptine. Acta Endocrinol (Copenh) 104:139–142

  34. Passos VQ, Souza JJS, Musolino NRC et al (2002) Long-term follow-up of prolactinomas: normoprolactinemia after bromocriptine withdrawal. J Clin Endocrinol Metab 87:3578–3582

    Article  PubMed  CAS  Google Scholar 

  35. Colao A, Di-Sarno A, Cappabianca P et al (2003) Withdrawal of long-term cabergoline therapy for tumoral and nontumoral hyperprolactinemia. N Engl J Med 349(21):2023–2033

    Article  PubMed  CAS  Google Scholar 

  36. Liuzzi A, Dallabonzana D, Oppizzi G, Verde GG, Cozzi R, Chiodini P, Luccarelli G (1985) Low doses of dopamine agonists in the long-term treatment of macroprolactinomas. N Engl J Med 313(11):656–659

    Article  PubMed  CAS  Google Scholar 

  37. Moriondo P, Travaglini P, Nissim M et al (1985) Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal. J Clin Endocrinol Metab 60:764–772

    Article  PubMed  CAS  Google Scholar 

  38. van ‘t Verlaat JW, Croughs RJ (1991) Withdrawal of bromocriptine after long-term therapy for macroprolactinomas: effect on plasma prolactin and tumour size. Clin Endocrinol (Oxf) 34:175–178

    Google Scholar 

  39. Jones SE, James RA, Hall K et al (2000) Optic chiasmal herniation–an under recognized complication of dopamine agonist therapy for macroprolactinoma. Clin Endocrinol (Oxf) 53(4):529–534

    Article  CAS  Google Scholar 

Download references

Acknowledgement

We are grateful to Edward Laws, Jr., for his critical evaluation and linguistic revision of this manuscript.

Author information

Authors and Affiliations

  1. Department of Neurosurgery, First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, P.R. China

    Zhe Bao Wu, Zhi Peng Su, Jin Sen Wu, Wei Ming Zheng, Qi Chuan Zhuge & Ming Zhong

Authors
  1. Zhe Bao Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Zhi Peng Su
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jin Sen Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Ming Zheng
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Qi Chuan Zhuge
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ming Zhong
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zhe Bao Wu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wu, Z.B., Su, Z.P., Wu, J.S. et al. Five years follow-up of invasive prolactinomas with special reference to the control of cavernous sinus invasion. Pituitary 11, 63–70 (2008). https://doi.org/10.1007/s11102-007-0072-4

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11102-007-0072-4

Keywords

Search

Navigation